Desloratadina

證據等級: L5

預測適應症: 0 個

Desloratadina: Evidence Pack Incomplete — No Repurposing Prediction Available

Summary

Desloratadina (Desloratadine) is a second-generation antihistamine widely used for allergic rhinitis and chronic urticaria. This Evidence Pack contains no TxGNN predicted indications, which means a drug repurposing evaluation cannot be completed at this stage. Additionally, the drug is not currently marketed in Italy under this INN, and key safety and MOA data are absent from the pack.

Quick Overview

Item	Content
Original Indication	Allergic rhinitis, chronic urticaria (general knowledge; not populated in Evidence Pack)
Predicted New Indication	Not available — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	N/A
Italy Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why This Report Cannot Be Completed

The Evidence Pack for Desloratadina is missing three critical components:

1. No TxGNN predictions were returned. The predicted_indications array is empty. Without at least one predicted indication, there is no repurposing candidate to evaluate. This may indicate the drug was not found in the TxGNN knowledge graph, or the prediction pipeline did not run to completion.

2. Mechanism of action data is absent. The original_moa field is marked as a data gap (severity: High). Desloratadine is known to be a selective peripheral histamine H₁-receptor antagonist — but this was not retrieved into the Evidence Pack. The DrugBank query returned one result (result_count: 1), yet the data was not populated, suggesting a pipeline extraction error.

3. Safety data is unavailable. Both key warnings and contraindications returned [Data Gap]. The TFDA package insert query also returned one result (result_count: 1) but was not parsed into the pack.

Italy Market Information

No Italian authorizations were found for DESLORATADINA under this exact INN.

Note: Desloratadine-containing products may be marketed under brand names (e.g., Aerius, Neoclarityn) with different INN spellings or combination formulations. A search under "desloratadine" (English spelling) is recommended.

Safety Considerations

Safety data was not successfully extracted into this Evidence Pack. Please refer to the EMA product information and the package insert for Desloratadine for current warnings, contraindications, and drug interactions.

The DDI query returned no interactions (query_status: not_found), which may reflect a search term mismatch rather than a true absence of known interactions.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is structurally incomplete — no predicted indications exist and critical drug-level data (MOA, safety) was not extracted despite successful upstream queries. A repurposing evaluation cannot be responsibly written without at least one TxGNN prediction to anchor the analysis.

To proceed, the following is needed:

Re-run TxGNN prediction pipeline using the correct DrugBank identifier for Desloratadine (DB00967) to generate predicted indications
Extract DrugBank data — the DrugBank query returned 1 result; confirm the extraction step did not silently fail, and populate original_moa, drugbank_id, and categories
Parse TFDA / EMA package insert — the insert query returned 1 result; extract warnings, contraindications, and approved indications into the Evidence Pack
Verify INN spelling — queries used DESLORATADINA (Italian/Spanish INN); confirm the TxGNN knowledge graph uses the same identifier, or remap to desloratadine (English INN / DrugBank standard)
Re-query Italy authorizations under alternate spellings or brand names to confirm true market absence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.